We evaluated two multi-analyte analyzers, the NOVA Stat Profile 1 (SP 1) and the NOVA Stat Profile 5 (SP 5). The SP 1 measures pH, Pco2' Po2' sodium, potassium, ionized calcium, and hematocrit in hepannized whole blood; the SP 5 determines all these analytes, plus chloride (not evaluated because it was unavailable at the time this study was initiated) and glucose. Interassay precision for pH, Pc' Po2, sodium, potassium, ionized calcium, and hematocrit (all on the SP 1) and glucose (on the SP 5) was excellent, the respective CVs (%) being: <0.006, 2.1, 3.0, 0.5, 1.7, 2.1 , <3.9, and 1 .2. Correlation with results obtained with Coming's Model 178, NOVA Biomedical's Model 6, Beckman's Astra 8, and Roche's Cobas-Bio was also excellent (r >0.975 for all analytes, r for hematocrit 0.865). Temperature-stability studies on whole-blood specimens maintained at 1 #{176}C indicated that results for all measured analytes were essentially uncharged for at least 2 h, except for potassium, which increased by 13% in 2 h. Blood-gas analysis usually includes measurement of pH, Pco2' and p, the results of which are used to calculate bicarbonate concentration and oxygen saturation. The combination of the measured and calculated variables is essential in the assessment of adequate blood perfusion, acidbase balance, and oxygen-carbon dioxide gas exchange. In addition, sodium, potassium, and chloride are oftentimes measured simultaneously in evaluating disturbances in renal function and water balance (1). Measurements of ionized calcium (Ca2) are known to be essential in cardiovascular management, hepatic transplantation, and evaluation of hypocalcemia (2-6). The need for glucose momtoring of critically ill and surgical patients is well known
287).
'Chloride was not included in this report becausethis analysis was not available on the SP 1 when the study was begun; both the SP 1 and SP 5 now include it.
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We evaluated the analytical performance ofthe SP 1 and ofthe glucose component ofthe SP 5 for precision, accuracy, reliability, and cost effectiveness in a laboratory designed to service the acute-care facilities (operating rooms, postanesthesia care unit, and special care unit) at Memorial
Sloan-Kettering
Cancer Center.
Materials and Methods

Instrumentation.
Results from the SP 1 were evaluated and correlated with data obtained with our routinely used instruments:
the Model 178 blood-gas analyzer (Ciba- for blood-gas analysis were used during the evaluation. Specimens were collected in 3-mL plastic syringes containing 60 USP units of dry lithium heparin and promptly chilled in an ice slurry. Duplicate specimens, collected for temperature stability studies, were maintained at room temperature (22 #{176}C) throughout the experiment. All analyses were performed in duplicate within 30 mm of collection (except analyses performed during the temperaturestability studies). Plasma glucose was determined in the same specimens collected for blood-gas analysis, which were centrifugated within 15 mm after the blood-gas analyses were completed. Instrument calibration. The Corning blood-gas analyzer was calibrated with two gas mixtures, one containing 50 mL of CO2 and 100 mL of 02 per liter and the second containing 100 mL of CO2 per liter. We calibrated the pH electrode with pH 6.838 and pH 7.382 phosphate buffers.
The two gas mixtures for calibrating the NOVA SP 1 and 5 for Pco2 and p2 measurements contained (a) 50 mL of CO2 and 200 mL of 02 per liter and (b) 100 mL of CO2 per liter. The electrodes were calibrated as follows: pH was calibrated with the phosphate buffers, the sodium glass electrodes with sodium at 75 and 140 mmoIJL, the potassium valinomycin electrode with potassium at 4.0 and 20.0 mmolJL, and the ionized calcium neutral carrier membrane electrode with calcium at 1.0 and 2.0 mmol/L. The SP 5 was calibrated for glucose at 800 and 2000 mg/L. All calibration solutions were maintained in a multi-reagent container (Fluid Pak) designed to provide sufficient calibrators and wash solution for between 600 and 1000 determinations, depending on work-load volume.
Sodium, potassium, and Ca2 were calibrated in the NOVA 6 at the following concentrations (mmolfL): sodium 100 and 140, potassium 4.0 and 40, and Ca2 1.0 and 2.0.
All calibration and wash fluids were supplied by NOVA was excellent, with CVs <4% over a glucose range of800 to Biomedical.
mgfL.
The glucose calibration set-points for the Astra 8 were 270 and 1450 mgIL.
The statistical data for each of the analytes are summarized in Table 2 . Because of sample-volume limitations, analysis on both the instruments being evaluated was not
Results always possible, as is reflected in an unequal number of
Interassay precision on the SP 1 and SP 5 was evaluated over 22-and 28-day periods, respectively. Table 1 Figure 1 demonstrates the percentage change in pH, Pco2, P , glucose, and potassium in whole-blood specimens mainined at 1 and 22 #{176}C. Sodium, calcium, and hematocrit were unaffected at temperatures of 1 and 22 #{176}C over a 2-h period. Because no glycolytic inhibitors were present in the heparinized wholeblood specimens, the glucose concentration decreased at the rate ofabout 6%/h in samples maintained at 22 #{176}C. The rate of glucose decline appeared to be related to the leukocyte count, which ranged between 25 000 and 100 000/L in the samples monitored. No significant change in glucose concentration was observed in specimens maintained at 1 #{176}C with leukocyte counts >50 00O/L. In specimens maintamed at 1 #{176}C, concentrations of extracellular potassium The SP 1 and SF 5 are instruments designed to assay multiple analytes in whole blood in 90 s or less. These instruments require daily maintenance of about 10 to 15 mm, and their various software features permit on-line monitoring of system status, maintenance check routines, estimation ofreagent and calibrator availability, and input ofpatient demographics.
The need for blood-gas and electrolyte determinations .
presupposes an exigency. In such circumstances the laboratory must provide accurate data rapidly. The major objectives ofall clinical laboratories are increased precision and accuracy, decreased TAT, increased efficiency, and decreased cost of operation. In an emergency or acute-care laboratory, the need for rapid results can be most efficiently met by analyzing whole blood, thus eliminating several SD 31.8
25.7
58.0 processing steps such as centrifugation, positive patient CV(%) Additional advantages are the reductions in sample volume requirements, specimen handling, and the associated risk of infection to laboratory workers.
Because whole blood is still viable, the metabolic process will continue at room temperature. Indeed, a serious cona Glucosewas analyzed in the Stat Profile 5; all other assays were performedin the Stat Profile1.
'cv or SD of comparisoninstruments (Coming178 andNOVA6) in routine usein laboratory.
CV of comparison instrument (Astra8) In routineuse in Iaboratoiy.
dcv of comparison instrument (Cobas-Bio) in routine useinlaboratory. If no change wasobeeved(I.e.,glucose at 1 'C), data were notpresentedin the figure cern related to analysis of whole blood is the possible deleterious effects of preanalytical sample handling. For example, glycolysis caused by erythrocytes and leukocytes in freshly drawn blood will affect the pH, Pc, p, and glucose concentration in the specimen (13, 14) . Thus specimens collected for blood-gas analysis are usually chilled, to reduce the glycolytic effect, and blood for glucose analysis is usually collected in test tubes containing fluoride as an antiglycolytic agent (15) and oxalate as an anticoagulant. Because specimens collected for blood-gas analysis are anticoagulated with heparmn and do not contain an antiglycolytic agent, special attention must be given to the preanalytical handling of specimens collected for both blood-gas and glucose analysis. Our studies indicated that specimens collected for blood-gas and glucose analyses are stable for 2 h if maintained at about 1 #{176}C. Whole-blood specimens collected and stored at room temperature for 30 mm will show significant changes in pH, Pco2, and p as well as glucose.
Of particular interest was the observationthat extracellular potassium increases in whole-blood specimens mainmined at 1 #{176}C, which can be explained by the slowing of the active transport Savings as great as 40% were realized for both reagent and disposables costs and 26% savings in quality-control materials. Including the benefit of staff consolidation, the use of the SP 1 in the satellite laboratory helped contribute to an annual savings of about $45,000.
The addition of glucose analysis on the SP 5 obviates the need for a glucose analyzer. We can expect that future technological progress in whole-blood analysis will add to the growing list of in vitro test procedures. An extension of this technology will also permit development of mobile self-contained analyzers capable of providing emergency laboratory service in the operating room, at the site of a medical emergency, and in the laboratory.
We conclude that their performance characteristics make the SP 1 and SP 5 ideal analyzers for the clinical chemistry and acute-care laboratories.
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